NEW YORK, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment in the FLINT trial has been completed. FLINT is a double blind, placebo controlled, multi-center Phase 2b clinical trial evaluating the treatment effects of OCA compared with placebo in adult nonalcoholic steatohepatitis (NASH) patients.
